News Archive.
A selection of past press releases and news coverage of CB Therapeutics.
December 20, 2021
Two esteemed doctors join CB Therapeutics in its exploration of innovative approaches to the production of novel psychedelics and cannabinoids so researchers can address the unmet needs of patient communities
SAN DIEGO, Dec. 20, 2021 (GLOBE NEWSWIRE) — CB Therapeutics today announces the appointments of Dr. Stephen Wright and Dr. Brian Barnett to its newly formed Medical Advisory Board.
December 9, 2021
CB Therapeutics and atai Life Sciences launch TryptageniX to sustainably supply and develop clinically relevant compounds to tackle the growing mental health crisis
SAN DIEGO (GLOBE NEWSWIRE) — CB Therapeutics, a synthetic biology company creating research molecules that are chemically identical to the psychedelics and cannabinoids currently being studied for their mental health benefits, believes their partnership with atai Life Sciences will help to meet the growing unmet needs of patients with mental health conditions.
August 24, 2021
CB Therapeutics Achieves Another Breakthrough with the Biosynthesis of DMT and Related Tryptamine-based Compounds
SAN DIEGO–(BUSINESS WIRE)–CB Therapeutics is happy to announce that it has been awarded two more patents for the novel methods of production of high value molecules using cutting-edge biosynthesis technologies. These patents (11,041,002B1 and 10,988,785B1) cover inventions on cellular agriculture breakthroughs for producing cannabinoids and precursors to various other compounds…
May 10, 2021
CB Therapeutics Closes on Oversubscribed Series A
SAN DIEGO–(BUSINESS WIRE)–CB Therapeutics Inc., the leading synthetic biology company focused on the development and biosynthetic production of existing and novel tryptamines and cannabinoids, is pleased to announce that it has closed an oversubscribed Series A funding round, filled entirely by re.Mind Capital, a fund launched by the psychedelics kingmaker, Christian Angermayer within Apeiron, his family office…
September 23, 2020
CB Therapeutics Achieves Major Breakthroughs in Downstream Processing and Purification, Paving the Way for Low-cost Cannabinoids, Tryptamines, and Their Analogs
SAN DIEGO–(BUSINESS WIRE)–CB Therapeutics Inc., has successfully refined its in-house downstream processing, allowing for 99.6% pure CBC. a rare cannabinoid molecule found in trace quantities in cannabis and hemp. Using these patent-pending techniques, CB Therapeutics is able to drive down the cost of purification in parallel with increasing the purity to over 99%, considered a major breakthrough for any type of purification process…
June 15, 2020
CB Therapeutics Ships First Order of Rare Cannabinoids to Colorado Client
SAN DIEGO–(BUSINESS WIRE)–CB Therapeutics, Inc. has shipped its first order of rare cannabinoids to a customer in Colorado, marking the company’s first commercial sale. The shipment of the rare cannabinoids will be used for trial formulations of edible products to test consumer acceptance in the market…
June 3, 2020
CB Therapeutics Achieves Another Breakthrough with the Biosynthesis of DMT and Related Tryptamine-based Compounds
SAN DIEGO–(BUSINESS WIRE)–CB Therapeutics, Inc. has achieved the first successful biosynthesis of DMT (N,N Dimethyltryptamine) and related tryptamine-based compounds in yeast and has filed a patent on their biosynthetic production process for DMT and related analogs. CB Therapeutics’ development of a DMT production process, and its patent application, closely follows the first biosynthetic production of psilocybin in yeast and the patent application for the process…
April 28, 2020
CB Therapeutics Advances its Intellectual Property Portfolio with New Patent Award for its Bioinformatics Platform
SAN DIEGO–(BUSINESS WIRE)–SAN DIEGO–(BUSINESS WIRE)–CB Therapeutics is a leading synthetic biotechnology company focused on the research and development of cellular agriculture for the production of cannabinoids, tryptamines and other therapeutics to advance Neuroscience. CB Therapeutics has been awarded a patent for its Bioinformatics platform for the creation and annotation of libraries of biosynthetic pathway genes from next generation sequencing data…
April 20, 2020
CB Therapeutics Enters into Collaboration Agreement with Cleveland Clinic for the Manufacture of Psilocybin, DMT and MDMA Therapeutic Compounds for Clinical Trials to Treat Depression, Addiction and PTSD
SAN DIEGO–(BUSINESS WIRE)–CB Therapeutics, Inc., having achieved the successful biosynthesis of psilocybin, psilocin and other related tryptamine-based compounds, has entered into a Memo of Understanding with the Cleveland Clinic to produce multiple therapeutic tryptamine compounds for clinical trials
December 4, 2019
CB Therapeutics Achieves Major Breakthrough in the Biosynthesis of Psilocybin, Psilocin and Related Tryptamine-based Compounds
SAN DIEGO–(BUSINESS WIRE) – CB Therapeutics, Inc. has achieved the successful biosynthesis of psilocybin, psilocin and related tryptamine-based compounds typically found in plants and fungi and has filed a patent for the production process…
November 14, 2019
CB Therapeutics Continues to Advance its Intellectual Property Portfolio with New Patent Awards
SAN DIEGO–(BUSINESS WIRE) – CB Therapeutics has been awarded a patent on Oct 10, 2019, titled “Isolated codon optimized Nucleic Acids”. This patent covers inventions related to the optimization of the entire biosynthetic cannabinoid pathway…
September 25, 2019
CB Therapeutics Advances Its Intellectual Property Portfolio for Its Cellular Agriculture Platform with New Patent Applications
SAN DIEGO–(BUSINESS WIRE) CB Therapeutics, Inc. has developed a patent-pending platform for creating and annotating libraries of biosynthetic pathway genes from next generation sequencing data. Processing and analyzing large amounts of raw biological data from diverse organisms is a significant bottleneck for gene discovery and biosynthetic pathway elucidation. Accelerating this process and increasing the breadth of organisms studied can drastically improve success in producing high-value natural products in microorganisms.
July 11, 2019
CB Therapeutics Achieves Key Production Milestone
SAN DIEGO–(BUSINESS WIRE) – “We are excited to announce that we have successfully achieved the titers we projected in our largest pilot level production bioreactor,” said Chief Scientific Officer Jacob Vogan. “We are ahead of schedule for our scale-up progress and have made further significant advancements in the scientific platform for fermentation-based cellular agriculture.” Sher Butt, the president and CEO of CB Therapeutics, added: “This key production milestone further de-risks our enterprise and is the last step towards large commercial scale production and customer delivery of a number of high value molecules by the fourth quarter of 2019. We look forward to the further development of our core science and achieving expected economies of scale for our production platform.”
March 20, 2019
CB Therapeutics Secures new Research and Production Facility
SAN DIEGO–(BUSINESS WIRE) – CB Therapeutics today announces that it is operating a new R&D and production facility in Southern California. The 7K sq. ft. site includes a research lab and a production space for laboratory scale and pilot production runs. The facility comes equipped with a suite of benchtop and large-scale fermenters ready to use in biosynthetic applications. This plug-and-play upgrade for CB Therapeutics greatly accelerates its path to bringing pure, therapeutic compounds to market.
September 28, 2018
As cannabis market heats up, local scientists race to build ‘weed biofactories’
SAN DIEGO TRIBUNE – Scientists are hustling on behalf of the weed industry to find new ways to produce the most valuable compounds in marijuana, ditching greenhouses in favor of steel vats…
